Key clinical point: Direct-acting antiviral therapy reduced risk of death, compared with no therapy in HCV-infected patients with a history of hepatocellular carcinoma.
Major finding: DAAs were associated with a significant reduction in risk of death among recovered HCC patients with HCV infections (HR, 0.54).
Study details: The data come from a retrospective study of 797 HCC patients with hepatitis C infection.
Disclosures: The study was funded in part by the National Cancer Institute and AbbVie. Dr. Singal disclosed relationships with companies including AbbVie, Gilead, Bayer, Eisai, Wako Diagnostics, Exact Sciences, Exelixis, Roche, Glycotest, and Bristol-Myers Squibb.
Singal AG et al. Gastroenterology. 2019. doi: 10.1053/j.gastro.2019.07.040.